Short-Term Debt to Equity Ratio: Annovis Bio, Inc. (ANVS)

This chart illustrates that the market value of Annovis Bio, Inc. (ANVS) is 0.00. The business's financial stability relies on the development of agents against neurotoxic proteins for the elderly via government procurement. The brand's high authority within the scientific community is supported by the prospects of bunitiazine in Alzheimer's therapy. However, profits remain at risk until the completion of Phase 3 trials, while the protection of rights to buntanetap forms the primary barrier for competitors.

This ratio compares the volume of liabilities with a maturity of up to one year against the market value of net assets, determining the company's degree of dependence on operational refinancing. For Annovis Bio, Inc. (ANVS), which develops long-term solutions against neurotoxicity, the short-term debt-to-equity ratio serves as an indicator of financial stability during the patent development period, where excessive leverage could create liquidity risks.